News

Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential
Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...
The Economist18h
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
FDA, Novo Nordisk, Warn Consumers About ‘Counterfeit’ Ozempic
The U.S. Food and Drug Administration (FDA) and drug manufacturer Novo Nordisk are warning consumers about “counterfeit” ...
Fierce Pharma6d
In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
Novo Nordisk: The Fear Is Overblown
Novo Nordisk saw a significant decline as it lost over 55% from its highs in June 2024. Check out the reasons for the decline ...
Yahoo Finance3d
Is Novo Nordisk A/S (NVO) The Best Stock to Buy and Hold For 10 Years?
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... Waiting on the sidelines could mean missing out and might not be the right strategy. Research has shown that ...